MiBio Meeting Series
The MIBio conference series engages leading experts from industry and academia in a discussion on how the latest molecular interaction-based discoveries can be exploited in biopharmaceutical formulation to produce more effective, patient-friendly, and safer therapeutic products.
We are delighted to announce that the 12th MIBio conference will take place at Howard Theatre, Downing College, Cambridge, on 04 December 2024.
MIBio engages leading experts from industry and academia in a discussion on how the latest molecular interaction-based discoveries can be exploited in biopharmaceutical formulation to produce more effective, patient-friendly, and safer therapeutic products.
The 2024 meeting will focus on a number of aspects of cutting edge biopharmaceutical product development, including patient-centric dosage forms, both from the formulation and from the device point of view. In addition, for the first time in the MIBio series, recent advances and future outlook in oral delivery will be discussed. Last but not least, presentations and discussions will cover development of novel dosage forms and the use of artificial intelligence to achieve better products.
We expect around 100 delegates from biopharma industry, academia and technology suppliers to create a stimulating event fostering new collaborations and discoveries that will help steer the development of the next generation of formulation technologies. We will be inviting abstracts for poster submissions and welcome applications for sponsor and exhibitor slots on the day.
We look forward to seeing you at MIBio 2024!
MiBio 2023 (11th)
The 11th MIbio2023 conference was held at the exquisite Howard Theatre, Downing College of University of Cambridge in Cambridge, UK. This one-day event was marked by a series of enlightening presentations, exciting posters and provided invaluable networking opportunities with representatives from both academia and industry. This conference was co-organized by the Royal Society of Chemistry (RSC) RSC Formulation Science and Technology (FSTG), and the Joint Colloids Group of the Society of Chemical Industry Chemical Industry (SCI) and Royal Society of Chemistry, together with the Academy of Pharmaceutical Science (APS).
This year's conference centred around cutting-edge advancements in biopharmaceutical product development. Dr. Didier PERTUY(Sanofi) discussed how drug delivery technologies are shaped by diverse modalities, emphasizing customer needs and ecosystems. Dr. Katie C. (AstraZeneca) explored the application of human factors in patient-centric dosage and device development, emphasizing a user-centred approach. Dr. Maria Chiara Arno (University of Birmingham) introduced a novel method for precision polymer particle manufacturing, potentially revolutionizing drug delivery applications. Dr. Stephen Buckley (Novo Nordisk), presented advanced strategies for oral peptide/protein delivery, delving into chemistry, enhancers, and novel devices/technologies. Additionally, Dr. Alistair Taverner (University of Bath) shared insights on the Permeable Inhibitor of Phosphatase (PIP) peptide, enhancing oral peptide absorption by targeting endogenous biological permeability regulation. Lastly, Professor Paul Dalby (University College London) elucidated the degradation and stabilization mechanisms in biologic formulations, employing biophysical analysis and molecular dynamics (MD) simulations.
Beyond the exceptional presentations, panel discussions explored strategies for biopharmaceutical drug delivery, including enhanced devices, patient-centric designs, and human factors. Formulation challenges for parenteral (subcutaneous, intravenous) administration were addressed, alongside innovative approaches involving alternative administration routes.
MiBio 2023 ♦ MiBio 2022 ♦ MiBio 2019 ♦ MiBio 2018
MiBio 2016 ♦ MiBio 2015 ♦ MiBio 2014 ♦ MiBio 2013 ♦ MiBio 2012